(Reuters) -Abbott Laboratories raised its annual profit forecast on Thursday after its second-quarter earnings edged past Wall Street estimates on double-digit growth in sales of its glucose monitors ...

The Libre Duo systems are the first glucose-ketone monitors to reach the diabetes market.

Wednesday, Abbott Laboratories (NYSE:ABT) reported first-quarter sales of $9.96 billion, up 10.8% on an organic basis for the underlying base business, beating the consensus of $9.88 billion. Reported ...

Discover some of the best medical device stocks to invest in, what makes them stand out, and key factors to consider before adding them to your portfolio.

Abbott’s strong medical devices sales boosted the company during the first part of 2024, beating Wall Street expectations and raising its forward-looking financial guidance. The company released its ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

April 17 (Reuters) - Abbott Laboratories (ABT.N), opens new tab beat Wall Street estimates for quarterly profit on Wednesday on robust sales of its medical devices, but the company's stock fell 3% in ...

Abbott Laboratories (NYSE: ABT) and Dexcom (NASDAQ: DXCM) are two leading medical device companies that compete against one another in the market for continuous glucose monitoring (CGM) systems. They ...

Low double-digit growth in quarterly medical device sales has pushed Abbott to nudge up its earnings projections for the year. The company’s second-quarter report follows FDA green lights earlier this ...

Illinois-based Abbott Laboratories (ABT) is a diversified healthcare company that develops and manufactures medical devices, ...